Hasil Pencarian - Rebecca Kaltman

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

    258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer oleh Benjamin Vincent, Dominic Moore, Mark Woodcock, Carey Anders, Amanda Van Swearingen, Maria Sambade, Luz Cuaboy, Amy Garrett, Karen McKinnon, Kristen Cowens, Dante Bortone, Benjamin Calhoun, Lisa Carey, Claire Dees, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, Jonathan Serody

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

    Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study oleh Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M. Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M. Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

    Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study oleh Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M. Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M. Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

    Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer oleh Karen McKinnon, Kristen Cowens, Dante Bortone, Lisa Carey, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, Carey K Anders, Mark G Woodcock, Amanda E D Van Swearingen, Dominic T Moore, Maria J Sambade, Sonia Laurie, Alexander Robeson, Oleg Kolupaev, Luz A Cuaboy, Amy L Garrett, Benjamin C Calhoun, Alec D Wilkinson, E Claire Dees, Benjamin G Vincent, Jonathan S Serody

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: